LYFE Sciences · Project HERA
Variant Interpretation · Classification Report
Variant classification summary
NM_000546.6:c.-136del
TP53
· NP_000537.3:p.?
· NM_000546.6
GRCh37: chr17:7590801 CT>C
·
GRCh38: chr17:7687483 CT>C
Gene:
TP53
Transcript:
NM_000546.6
Final call
VUS
PM2 supporting
Variant details
Gene
TP53
Transcript
NM_000546.6
Protein
NP_000537.3:p.?
gnomAD AF
ClinVar
OncoKB
Classification rationale
Interpretation summary
Generated evidence synthesis
1
VUS: PM2 (supporting) reflects absence from gnomAD v2.1 and v4.1, below the VCEP's 0.003% threshold.
Final determination:
Under the ClinGen TP53 VCEP Version 2.4 point-based framework, PM2 supporting contributes 1 point, and totals from -1 through 5 are classified as VUS.
Criteria assessment
ACMG/AMP criteria review
Criteria shown when status is available
All criteria require review: For research and educational purposes only.
| Criterion | Status | Rationale | Evidence used |
|---|---|---|---|
| PVS1 | N/A | Not applicable: c.-136del is a 5′-UTR exon 1 deletion, not a VCEP-listed null or canonical splice variant, with maximum SpliceAI delta 0.004. |
cspec
vcep_pvs1_flowchart
vcep_pvs1_splicing_worksheet
spliceai
|
| PS1 | N/A | Not applicable: c.-136del is a 5' untranslated-region deletion with no amino-acid change for comparison under the TP53 PS1 rule. |
cspec
|
| PS2 | Not assessed | Not assessed: no proband, parental-testing, or de novo observation is available to assign the VCEP's 1-, 2-3-, 4-7-, or ≥8-point PS2 strength. |
cspec
vcep_table_of_lfs_cancers_and_points_for_ps2_and_pp1_code_application
|
| PS3 | N/A | Not applicable: c.-136del is an upstream 5' untranslated-region deletion with p.? rather than a missense or small in-frame deletion covered by the TP53 functional framework. |
cspec
vcep_flowchart_for_application_of_functional_rule_codes
vcep_functional_worksheet
|
| PS4 | Not assessed | Not assessed: no proband phenotype, LFS criteria, cancer age, or case-control counts are available to calculate the VCEP PS4 points. |
cspec
vcep_ps4_points_table
|
| PM1 | N/A | Not applicable: c.-136del is a non-missense 5' untranslated-region deletion, outside both TP53 VCEP PM1 routes requiring missense variants. |
cspec
|
| PM2 | Met | Met at supporting: the variant is absent from gnomAD v2.1 and v4.1, giving observed frequency 0 below the 0.003% PM2 threshold. |
cspec
gnomad_v2
gnomad_v4
|
| PM3 | N/A | Not applicable: the TP53 VCEP explicitly excludes PM3 for TP53/Li-Fraumeni syndrome, regardless of available phase or affected-proband observations. |
cspec
|
| PM4 | N/A | Not applicable: the TP53 VCEP Version 2.4 CSPEC entry explicitly marks PM4 as Not Applicable. |
cspec
|
| PM5 | N/A | Not applicable: c.-136del has no amino-acid residue, while TP53 PM5 requires a missense variant and a different classified missense variant at that residue. |
cspec
|
| PM6 | N/A | Not applicable: the TP53 VCEP explicitly designates PM6 as Not Applicable. |
cspec
|
| PP1 | Not assessed | Not assessed: no family genotypes or meioses are available to compare with the VCEP thresholds of 3-4, 5-6, or ≥7 cosegregating meioses. |
cspec
vcep_table_of_lfs_cancers_and_points_for_ps2_and_pp1_code_application
|
| PP2 | N/A | Not applicable: the TP53 VCEP explicitly designates PP2 as not applicable for this framework. |
cspec
|
| PP3 | N/A | Not applicable: c.-136del is a 5′ UTR deletion, outside the VCEP PP3 scopes for missense, in-frame deletion, and splice variants. |
cspec
vcep_flowchart_for_application_of_pp3_2c_bp4_2c_and_bp7
|
| PP4 | Not assessed | Not assessed: no multigene-panel blood observations or variant allele fractions are available for the VCEP PP4 thresholds. |
cspec
|
| PP5 | N/A | Not applicable: the TP53 VCEP expressly prohibits use of PP5 for this specification. |
cspec
|
| BA1 | Not met | Not met: the variant is absent from gnomAD v2.1 and v4.1, so its observed frequency is below the 0.1% BA1 threshold. |
cspec
gnomad_v2
gnomad_v4
|
| BS1 | Not met | Not met: the variant is absent from gnomAD v2.1 and v4.1, rather than having a 0.03%–less-than-0.1% qualifying population frequency. |
cspec
gnomad_v2
gnomad_v4
|
| BS2 | Not assessed | Not assessed: no carrier-level data identify unrelated cancer-free women aged at least 60 years from one source. |
cspec
gnomad_v2
gnomad_v4
|
| BS3 | N/A | Not applicable: c.-136del is an upstream 5' untranslated-region deletion with p.? rather than a missense or small in-frame deletion covered by the TP53 functional framework. |
cspec
vcep_flowchart_for_application_of_functional_rule_codes
vcep_functional_worksheet
|
| BS4 | Not assessed | Not assessed: no affected family members with genotype results are available to demonstrate the VCEP-defined lack of segregation required for BS4. |
cspec
vcep_table_of_lfs_cancers_and_points_for_ps2_and_pp1_code_application
|
| BP1 | N/A | Not applicable: the TP53 VCEP excludes BP1 because truncating variants account for only a portion of TP53 disease-causing variants. |
cspec
|
| BP2 | N/A | Not applicable: the TP53 VCEP marks BP2 Not applicable, so phase-confirmed trans observations cannot establish this criterion under version 2.4. |
cspec
|
| BP3 | N/A | Not applicable: the TP53 VCEP Version 2.4 CSPEC entry explicitly marks BP3 as Not Applicable. |
cspec
|
| BP4 | N/A | Not applicable: c.-136del is a 5′ UTR deletion, outside the VCEP BP4 scopes for missense, in-frame deletion, silent, and intronic variants. |
cspec
vcep_flowchart_for_application_of_pp3_2c_bp4_2c_and_bp7
|
| BP5 | N/A | Not applicable: the TP53 VCEP marks BP5 as not applicable for this specification. |
cspec
|
| BP6 | N/A | Not applicable: the TP53 VCEP expressly prohibits use of BP6 for this specification. |
cspec
|
| BP7 | N/A | Not applicable: c.-136del is a 5′ UTR deletion, not the synonymous or intronic variant required by the VCEP BP7 rule. |
cspec
vcep_flowchart_for_application_of_pp3_2c_bp4_2c_and_bp7
|
Disclaimer:
The content and results provided by LYFE Sciences are for research and educational purposes only and must not be used as a substitute for professional medical judgment, diagnosis, or treatment. Always consult a qualified healthcare professional before making any clinical decisions.